This trial will test if two drugs can improve exercise endurance and muscle function in people with heart failure.
1 Primary · 12 Secondary · Reporting Duration: Week 6
Active Control
Non-Treatment Group
53 Total Participants · 3 Treatment Groups
Primary Treatment: Empagliflozin + Potassium Nitrate (KNO3) · Has Placebo Group · Phase 2
Age 18 - 90 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: